Estrella immunopharma, inc.ESLA.US Overview

US StockHealthcare

(No presentation for ESLA)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

ESLA Overall Performance

ESLA AI Analysis & Strategy

ESLA Recent Performance

6.52%

Estrella immunopharma, inc.

0.81%

Avg of Sector

-1.14%

S&P500

ESLA PowerScanner

ESLA Key Information

ESLA Valuation Metrics

ESLA Earnings Table

ESLA Profile

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.